Clinical Trial News and Research

RSS

CEI releases new diabetes market forecast study

Since 2008, Cutting Edge Information has developed forecasting data for the diabetes treatment market. The new report -- "Diabetes Market Forecast to 2015" -- provides a deep analysis of the relevant clinical, commercial, and market trends affecting diabetes therapeutics today and their impact leading into the next decade. In addition to detailed drug, class, and company profiles, the study includes primary research findings generated from survey data and interviews with leading physicians and marketing executives.

7 Jan 2010

Cedars-Sinai Heart Institute selected as top 25 hospitals for cardiac bypass surgery

Worth magazine has selected Cedars-Sinai Heart Institute as one of the United States' top 25 hospitals for cardiac bypass surgery.

7 Jan 2010

ProFibrix B.V. receives loan up to $7.4 million to develop its new hemostat Fibrocaps

ProFibrix B.V., a leader in the development of innovative products for hemostasis and regenerative medicine, today announced that SenterNovem, an agency of the Dutch Ministry of Economic Affairs, has granted the company a loan under its new Innovation Credit scheme of potentially up to EUR 5 million to finance the further clinical development of its unique new hemostat Fibrocaps(TM).

7 Jan 2010

Nutrient mix shows potential to improve memory in Alzheimer's patients

In the early stages of Alzheimer's disease, patients typically suffer a major loss of the brain connections necessary for memory and information processing. Now, a combination of nutrients that was developed at MIT has shown the potential to improve memory in Alzheimer's patients by stimulating growth of new brain connections.

7 Jan 2010

Phase II clinical trial results of Liposome-Entrapped Paclitaxel announced

NeoPharm, Inc. today announced the results of a Phase II clinical trial of Liposome-Entrapped Paclitaxel (LEP) an active component of Taxol®. This multicenter, open-label trial of LEP was conducted at 5 centers in India.

7 Jan 2010

Phase II clinical trial of Gilead Sciences' elvitegravir, GS 9350 and Truvada meets primary objective

Gilead Sciences, Inc. today announced that a Phase II clinical trial of its investigational integrase inhibitor-based, once-daily, fixed-dose “Quad” regimen of elvitegravir, GS 9350 and Truvada® (emtricitabine and tenofovir disoproxil fumarate) for the treatment of HIV-1 infection met its primary objective.

7 Jan 2010

Study explains how H. pylori infection causes stomach cancer

Researchers report that Helicobacter pylori, the only bacterium known to survive in the harsh environment of the human stomach, directly activates an enzyme in host cells that has been associated with several types of cancer, including gastric cancer.

7 Jan 2010

Tumor Biology Center to initiate Phase 2 clinical trial with CytRx’s INNO-206

CytRx Corporation, a biopharmaceutical company, today announced that the Tumor Biology Center, Freiburg, Germany, plans to initiate a Phase 2 clinical trial with CytRx’s doxorubicin prodrug INNO-206 as a treatment for patients with advanced pancreatic cancer.

6 Jan 2010

OncoGenex Pharmaceuticals receives grant funding for Phase 2 clinical trial of OGX-427

OncoGenex Pharmaceuticals, Inc., today announced that a randomized, controlled, investigator-sponsored Phase 2 clinical trial evaluating OGX-427 when administered as a monotherapy to patients with castrate resistant prostate cancer (CRPC) has received grant funding.

6 Jan 2010

International Headache Society publishes new guidelines to stimulate more research on headache treatment

If you're one of the millions of headache sufferers around the world, more effective relief might be on the way in years to come. That's because the International Headache Society has just published new research guidelines intended to stimulate more research into headache treatment, and to provide researchers with guidelines to cut health risks associated with treatment.

6 Jan 2010

Treatment with Effient more cost effective, show TRITON-TIMI 38 clinical trial results

Results from a health economic substudy of the TRITON-TIMI 38 clinical trial showed that among patients with acute coronary syndromes (ACS) managed with percutaneous coronary intervention (PCI), including stenting, treatment with Effient(®) (prasugrel) compared with branded clopidogrel (Plavix(®)) was more cost effective, and in most cases cost saving.

6 Jan 2010

Patient enrolled in Phase I clinical study of two investigational compounds: MK-2206 and AZD6244

Dr. Anthony Tolcher, clinical director for South Texas Accelerated Research Therapeutics (START) at the START Center for Cancer Care in San Antonio, announced today that the first patient has been enrolled in a groundbreaking Phase I clinical trial of a novel combination anticancer regimen composed of two investigational compounds: MK-2206 from Merck & Co., Inc. and AZD6244 (ARRY-886*) from AstraZeneca.

6 Jan 2010

Keryx Biopharmaceuticals reaches SPA agreement for Phase 3 clinical program for Zerenex

Keryx Biopharmaceuticals, Inc. announced today that it has reached agreement with the U.S. Food and Drug Administration (FDA) regarding a Special Protocol Assessment (SPA) on the design of a Phase 3 clinical program for Zerenex(TM) (ferric citrate), its iron-based phosphate binder for the treatment of elevated serum phosphorous levels, or hyperphosphatemia, in patients with end-stage renal disease (ESRD).

6 Jan 2010

Pharsight releases Phoenix NLME and Phoenix Connect

Pharsight, a market-leading provider of software and scientific services to improve productivity and decision-making in clinical drug development, today announced that it has released two new data analysis tools; Phoenix NLME and Phoenix Connect.

6 Jan 2010

Phase I clinical trial for Intellikine's INK128 inhibitor initiated

Intellikine, Inc. has initiated a Phase I clinical trial for its targeted anticancer drug INK128, a novel orally-available small molecule inhibitor of both the TORC1 and TORC2 complexes, key components of the PI3K/mTOR signaling pathway.

6 Jan 2010

Scott & White's CRI launches two clinical trials targeting cancers

Scott & White's Cancer Research Institute (CRI) has launched two clinical trials targeting cancers that affect both adults and children.

6 Jan 2010

IBI initiates Phase 2/3 pivotal clinical trial to assess the safety and efficacy of IBI-10090

Icon Bioscience, Inc., (IBI), a privately held biopharmaceutical company that specializes in the development and commercialization of novel ophthalmic pharmaceuticals announced today that it has initiated its Phase 2/3 pivotal clinical trial to assess the safety and efficacy of IBI-10090 in patients undergoing cataract surgery.

6 Jan 2010

Quercetin may prevent hepatitis C infection; findings may lead to less toxic treatments

Researchers have identified two cellular proteins that are important factors in hepatitis C virus infection, a finding that may result in the approval of new and less toxic treatments for the disease, which can lead to liver cancer and cirrhosis.

6 Jan 2010

Cancer Research UK and CRT to undertake phase I clinical trial of DI-B4

CANCER RESEARCH UK and Cancer Research Technology (CRT), the charity's development and commercialisation arm, are to undertake a phase I clinical trial of an investigational monoclonal antibody1 drug from Merck KGaA, Darmstadt, Germany, called DI-B4 - it is announced today (Monday).

6 Jan 2010

Enrollment in Boston Scientific's MAPS clinical trial completed

Boston Scientific Corporation today announced that it has completed enrollment in its MAPS(TM) clinical trial, which is studying the coiling of intracranial aneurysms.

6 Jan 2010

Clinical Trial News and Research

CEI releases new diabetes market forecast study

Cedars-Sinai Heart Institute selected as top 25 hospitals for cardiac bypass surgery

ProFibrix B.V. receives loan up to $7.4 million to develop its new hemostat Fibrocaps

Nutrient mix shows potential to improve memory in Alzheimer's patients

Phase II clinical trial results of Liposome-Entrapped Paclitaxel announced

Phase II clinical trial of Gilead Sciences' elvitegravir, GS 9350 and Truvada meets primary objective

Study explains how H. pylori infection causes stomach cancer

Tumor Biology Center to initiate Phase 2 clinical trial with CytRx’s INNO-206

OncoGenex Pharmaceuticals receives grant funding for Phase 2 clinical trial of OGX-427

International Headache Society publishes new guidelines to stimulate more research on headache treatment

Treatment with Effient more cost effective, show TRITON-TIMI 38 clinical trial results

Patient enrolled in Phase I clinical study of two investigational compounds: MK-2206 and AZD6244

Keryx Biopharmaceuticals reaches SPA agreement for Phase 3 clinical program for Zerenex

Pharsight releases Phoenix NLME and Phoenix Connect

Phase I clinical trial for Intellikine's INK128 inhibitor initiated

Scott & White's CRI launches two clinical trials targeting cancers

IBI initiates Phase 2/3 pivotal clinical trial to assess the safety and efficacy of IBI-10090

Quercetin may prevent hepatitis C infection; findings may lead to less toxic treatments

Cancer Research UK and CRT to undertake phase I clinical trial of DI-B4

Enrollment in Boston Scientific's MAPS clinical trial completed

eBook: Using iPSCs models for human disease research and drug discovery eBook

Latest eBooks

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Driving innovation in Korean drug development

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer